Clinical trials: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease
Detecting Liver Fibrosis in Patients At-risk
The project will establish a research cohort (called STELIR; STEatotisk Liver-risk In Rogaland) based on a biobank with an associated health register.
- Conditions
- Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease, Nash, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
- Trial name
- STELIR (NCT07775638)
- Testing
- Routine study procedure
- Where
- Norway
- Volunteers
- 1,200 people
- Sponsor
- Helse Stavanger HF
Metabolic Dysfunction-associated Steatotic Liver Disease
Risk Factors and Impact MASLD in Patients With IBD
Inflammatory bowel disease (IBD) is a chronic disease characterized by remitting and relapsing inflammation of the gastrointestinal tract.
- Trial name
- MASLD (NCT06328452)
- Testing
- FibroScan
- Volunteers
- 120 people
- Sponsor
- Assiut University
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis
This study will evaluate the safety, feasibility, and preliminary effects of S-adenosyl-L-methionine (SAMe) compared with placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis.
- Trial name
- SAMeMASLDc-02 (NCT07495995)
- Testing
- S-adenosyl-L-methionine (SAMe), Placabo
- Volunteers
- 94 people
- Sponsor
- Cedars-Sinai Medical Center
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease NAFLD
Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition linked to excess body fat, high blood lipids, and other metabolic problems.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease NAFLD, Dyslipidemia, Obesity & Overweight
- Trial name
- TGP-MASLD (NCT07692438)
- Testing
- Taiwan green propolis capsule
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
Heterozygous Familial Hypercholesterolemia
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
- Trial name
- STEATO-FH (NCT06634160)
- Testing
- Fibroscan, Sample collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease
This prospective, single-center pilot study will evaluate metabolic flux dysregulation in adults with obesity and suspected or confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) who are scheduled for…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Obesity, Bariatric Surgery
- Trial name
- MASLD (NCT07760909)
- Testing
- Bariatric surgery, Stable isotope tracer infusion, MRI/MRE
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Prognostic Model for MASLD Related Cirrhosis
This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months.
- Trial name
- NCT07082751
- Testing
- Lifestyle Guidance
- Where
- 9 sites in China
- Volunteers
- 228 people
- Sponsor
- Beijing Friendship Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity, Hyperuricemia
- Trial name
- NCT07001865
- Where
- China
- Volunteers
- 17,040 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT06768216
- Testing
- Indianized version of Mediterranean Diet, Low Fat Diet, Physical Activity
- Where
- India
- Volunteers
- 134 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Integrating Hepatological, Nutritional, and Psychological Support as a Multidisciplinary Management to Improve Long-term Clinical Outcomes in MASLD
Metabolic dysfunction associated Steatotic Liver Disease (MASLD) is frequently complicated by cardiometabolic (CMR) comorbidities, and prognosis is substantially influenced by acute cardiovascular events (ACE).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, Cardiovascular Events
- Trial name
- CoCoNut (NCT07366463)
- Testing
- Hepatologic-provided recommendations, Nutritional support, Psychological support
- Where
- Italy
- Volunteers
- 286 people
- Sponsor
- University of Campania Luigi Vanvitelli
Risk Factors, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Risk of MASLD in Adults in Romania
This study aims to evaluate the presence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) risk factors and estimate the probability of advanced liver disease in a Romanian cohort from the European Health…
- Trial name
- MASLD Ro (NCT06864845)
- Where
- 2 sites in Romania
- Volunteers
- 5,340 people, healthy volunteers welcome
- Sponsor
- Internist.Ro
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Thermoacoustic Method for Estimating Liver Fat Fraction
The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements.
- Trial name
- NCT07321925
- Testing
- Thermoacoustic Enhanced Ultrasound
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Endra Lifesciences
Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty
This study will look at the health characteristics of adults with metabolic dysfunction-associated steatotic liver disease (MASLD) in Kazakhstan.
- Trial name
- NCT07889999
- Where
- 7 sites in Kazakhstan
- Volunteers
- 420 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Healthy, Simple Steatosis (SS)
New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
The goal of this observational study is to learn if some components of blood or exhaled breath can diagnose people having more fat in their livers than is normal, because of their poorer metabolic health (for example, because of…
- Conditions
- Healthy, Simple Steatosis (SS), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Trial name
- NCT06647095
- Testing
- D-Limonene Gelcaps, Fish Oil Concentrate, 1000 Mg Oral Capsule
- Where
- 2 sites in Czechia
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- General University Hospital, Prague
Fatty Liver Disease, Type 2 Diabetes
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
- Conditions
- Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
- Trial name
- NCT04283942
- Testing
- Intermittent calorie restriction (ICR), Continuous calorie restriction (CCR)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver…
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT07518784
- Testing
- LiverScope® exam, MR exam, Blood draw
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Diego
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Children
Screening and Intervention of MASLD in Children
Non-alcoholic fatty liver disease (NAFLD) in children and adolescents has recently been renamed metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT06905795
- Testing
- Fibroscan test, Nutrition guidance, Increase physical activity
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- NCT06493253
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- United States
- Volunteers
- 1,519 people
- Sponsor
- PharmaNest, Inc